Striking dichotomy in outcome of MYCN‐amplified neuroblastoma in the contemporary era
Open Access
Abstract
BACKGROUND: The authors exploited a large database to investigate the outcomes of patients with high‐risk neuroblastoma in the contemporary era.METHODS: All patients with high‐risk neuroblastoma aged 18 months with MYCN‐nonamplified [MYCN(−)] stage 4 disease.RESULTS: A complete response/very good partial response (CR/VGPR) to induction was correlated with significantly superior event‐free survival (EFS) (P < .001) and overall survival (OS) (P < .001) compared with a partial response or less. Patients with MYCN(+) and MYCN(−) disease had similar rates of CR/VGPR to induction (P = .366), and those with MYCN(+) and MYCN(−) disease who attained a CR/VGPR had similar EFS (P = .346) and OS (P = .542). In contrast, only MYCN(+) patients had progressive disease as a response to induction (P < .001), and early death from progressive disease (P < .001) among those with MYCN(+) disease. Overall, among patients who had a partial response or less, MYCN(+) patients had significantly inferior EFS (P < .001) and OS (P < .001) compared with MYCN(−) patients, which accounted for the significantly worse EFS (P = .008) and OS (P = .002) for the entire MYCN(+) cohort versus the MYCN(−) cohort.CONCLUSIONS: Patients with MYCN(−), high‐risk neuroblastoma display a broad, continuous spectrum with regard to response and outcome, whereas MYCN(+) patients either have an excellent response to induction associated with good long‐term outcome or develop early progressive disease with a poor outcome. This extreme dichotomy in the clinical course of MYCN(+) patients points to underlying biologic differences with MYCN(+) neuroblastoma, the elucidation of which may have far‐reaching implications, including improved risk classification at diagnosis and the identification of targets for treatment. Cancer 2014;120:2050–2059. © 2014 American Cancer Society.Keywords
This publication has 47 references indexed in Scilit:
- Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First RemissionJournal of Clinical Oncology, 2012
- Ifosfamide, carboplatin, and etoposide for neuroblastomaCancer, 2012
- Long-term results and risk profiles of patients in five consecutive trials (1979–1997) with stage 4 neuroblastoma over 1 year of ageCancer Letters, 2003
- Disseminated Neuroblastoma in Children Older Than One Year at Diagnosis: Comparable Results With Three Consecutive High-Dose Protocols Adopted by the Italian Co-Operative Group for NeuroblastomaJournal of Clinical Oncology, 2003
- Intensified Chemotherapy Increases the Survival Rates in Patients With Stage 4 Neuroblastoma With MYCN AmplificationJournal of Pediatric Hematology/Oncology, 2002
- Chronic neuroblastomaCancer, 2002
- Long‐term survival of children with neuroblastoma prior to the neuroblastoma screening project in GermanyMedical and Pediatric Oncology, 2002
- Outcome of high‐risk neuroblastoma using a dose intensity approach: Improvement in initial but not in long‐term resultsMedical and Pediatric Oncology, 2001
- Cyclophosphamide Plus Topotecan in Children With Recurrent or Refractory Solid Tumors: A Pediatric Oncology Group Phase II StudyJournal of Clinical Oncology, 2001
- Hyperfractionated Low-Dose Radiotherapy for High-Risk Neuroblastoma After Intensive Chemotherapy and SurgeryJournal of Clinical Oncology, 2001